Pilocarpine Formulation Stability via Single-Buffer Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia lack effective topical solutions, with existing pharmaceutical compositions experiencing stability issues and causing irritation, limiting options for patients who do not wish to undergo surgery or use corrective lenses.
Innovation Solution
Development of reduced buffer content compositions, specifically pilocarpine hydrochloride solutions with a single uniform buffering component, providing a higher concentration of pilocarpine relative to buffers, which enhance stability and reduce irritation, maintaining pH stability and pilocarpine retention in the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional buffer systems (multiple buffer components) are used in pilocarpine formulations, then pH stability is maintained, but formulation complexity increases and stability issues occur
Solution Approach 1:
The patent extracts and eliminates unnecessary buffer components from traditional multi-component buffer systems. By using only a single buffer component (phosphate, citrate, or borate) at optimized concentrations, the formulation achieves pH stability without the complexity and stability issues associated with multiple buffer components.
Solution Approach 2:
The patent changes the concentration parameters of buffer components significantly. By reducing buffer concentrations to specific ranges (phosphate: 0.01-0.1M, citrate: 0.01-0.05M, borate: 0.01-0.05M) and optimizing the ratio of pilocarpine to buffer, the formulation achieves stability with reduced complexity.
2Quantity of substance
If higher concentrations of pilocarpine are used relative to buffers, then treatment efficacy is improved, but formulation stability becomes more challenging
Solution Approach 1:
The patent optimizes the concentration ratio parameter between pilocarpine and buffer components. By maintaining pilocarpine concentrations of 0.1-10% w/v with specific buffer-to-pilocarpine ratios, the formulation achieves both high efficacy and stability.
Solution Approach 2:
The patent creates a composite formulation system combining pilocarpine hydrochloride with single-component buffer systems. This composite approach allows high pilocarpine concentrations while maintaining stability through the synergistic interaction between the active ingredient and optimized buffer components.
3Object-affected harmful factors
If reduced buffer content is used in pilocarpine formulations, then irritation is reduced, but pH stability may be compromised
Solution Approach 1:
The patent changes the buffer concentration parameters to reduced but optimized levels. By using phosphate buffers at 0.01-0.1M, citrate at 0.01-0.05M, or borate at 0.01-0.05M, the formulation reduces irritation while maintaining adequate pH stability through the optimized buffer capacity at these lower concentrations.
4Device complexity
If single uniform buffer components are used instead of multiple buffers, then formulation simplicity increases, but pH buffering capacity may be reduced
Solution Approach 1:
The patent compensates for the reduced buffering capacity of single-component systems by optimizing buffer concentration parameters. By using phosphate at 0.01-0.1M, citrate at 0.01-0.05M, or borate at 0.01-0.05M, each single buffer component provides sufficient buffering capacity for the intended pH range and application conditions.
Data Source
AI summary
Disclosed herein, are, among other things, stable, pharmaceutically acceptable and ophthalmologically suitable reduced buffer content and reduced buffering capacity pilocarpine compound compositions. In aspects, such compositions comprise therapeutically effective amounts of a pilocarpine compound, an effective amount of a uniform buffer component, wherein the concentrations of pilocarpine compound and uniform buffer component are limited to specific relative amounts and wherein the uniform buffer component is defined by one or more markedly distinguishing characteristics from buffers used in developed pilocarpine products (e.g., a unique pKa and/or concentration). Aspects of the invention include compositions defined by unique concentrations of such and other ingredients. Such compositions surprisingly exhibit pharmaceutically acceptable stability and, in aspects, stability equal to or statistically significantly greater than that of one or more on-market/developed reference product(s). Further, the invention provides methods of manufacturing such and similar compositions, and methods of their use in treating ocular conditions such as presbyopia.